Medicine for radically treating tertian malaria

• Main Authors: PI LIANG, LI JUN, HUANG SONG, MAO WEI, LU YUXIN, YANG ZHAOSHU, HUANG YAMING, YU JINGMAO, WEI SHUJIAO, HUANG CHAO, LIN KANGMING, PAN MAOHUA, ZOU CHUNYAN, QIN PI'EN, YANG ZHAOQING, WEI XIAOSHENG, HE XI, LI HUANGYI, YANG ZHAOKUN, ZHAO LUYI, QIN YUCHENG, ZENG WEILIN
• Format: Patent
• Language: Chinese; English
• Published: 15.09.2020
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention discloses a medicine which is prepared from an artemisinin compound and a macrolide compound and can be used for radically treating tertian malaria. The weight ratio of the artemisinin compound to the macrolide compound in the medicine is (20-300):(100-3000). Researches prove that the medicine can radically treat tertian malaria patients with CYP2D6 gene defects with multiple times of recurrence after repeated radical treatment (after radical treatment is invalid) of standard dosage of chloroquine combined with primaquine, and no recurrence of the patients occurs after observation for more than 40 weeks. Therefore, the medicine is particularly suitable for patients with human cytochrome P450 isozyme (CYP2D6) gene defects, and can achieve double effects of effective treatmentand precise radical treatment on the patients. 本发明公开了青蒿素类化合物与大环内酯类化合物可用于制备根治间日疟的药物，该药物中青蒿素类化合物与大环内酯类化合物的重量比为20-300:100-3000。研究证实，该药物对因CYP2D6基因缺陷的间日疟病人经标准剂量的氯喹合并伯氨喹啉反复根治多次复发后(根治无效后)进行根治，经过40多周的观察未见病人再复发。因此，该药物特别适用于人细胞色素P450同工酶